Kevin Rakin Appointed to the Histogenics Board of Directors
WALTHAM, Mass. -- December 03, 2012
Histogenics Corp., a biologics company that combines cell therapy and tissue
engineering technologies to develop highly innovative products primarily for
orthopaedic tissue repair and regeneration, today announced the appointment of
Kevin L. Rakin to its Board of Directors. Mr. Rakin has over 20 years of
experience in the biotechnology industry and most recently served as President
of Regenerative Medicine at Shire plc.
“We are very pleased to welcome Kevin to the Histogenics Board of Directors.
His broad experience in biotechnology and regenerative medicine over a 20 year
career will be extremely valuable during this exciting time for the company,”
said Patrick O’Donnell, President and Chief Executive Officer of Histogenics.
“We believe that Kevin’s experience with regenerative medicine treatments and
understanding of niche markets will help us advance the clinical development
program of NeoCart® and prepare it for commercialization.”
Kevin Rakin was most recently the President of Regenerative Medicine at Shire
plc, a leading specialty biopharmaceutical company. Prior to joining Shire,
Mr. Rakin served as the Chairman and CEO of Advanced BioHealing (ABH) from
2007 until its acquisition by Shire for $750 million in June 2011. Before
this, he served as the interim CEO of ABH and executive-in-residence at Canaan
Partners. Previously, he was a co-founder, President and Chief Executive
Officer of Genaissance Pharmaceuticals Inc., a publicly held pharmacogenomics
company, until its merger with Clinical Data Inc. in October 2005.
He currently serves on the executive committee for Connecticut United for
Research Excellence (CURE), Connecticut’s bioscience cluster. He has
previously served as a board member for Ipsogen SA, Vion Pharmaceuticals Inc.,
OMRIX Biopharmaceuticals Inc. and Clinical Data Inc. Mr. Rakin holds an M.B.A.
from Columbia University and received his graduate and undergraduate degrees
in Commerce from the University of Cape Town, South Africa.
Histogenics is a leading regenerative medicine company that combines cell
therapy and tissue engineering technologies to develop highly innovative
products for tissue repair and regeneration. In May of 2011, Histogenics
acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship
products focus on the treatment of active patients suffering from articular
cartilage derived pain and immobility. The Company takes an interdisciplinary
approach to engineering neocartilage that looks, acts and lasts like hyaline
cartilage. It is developing new treatments for sports injuries and other
orthopedic conditions, where demand is growing for long-term alternatives to
joint replacement. Histogenics has successfully completed Phase 1 and Phase 2
clinical trials in which the NeoCart autologous tissue implant’s effectiveness
is compared to that of standard microfracture surgery. Based in Waltham,
Massachusetts, the company is privately held. For more information,
For Histogenics Corp.
Cory Tromblee, 781-235-3060
Press spacebar to pause and continue. Press esc to stop.